Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 10 of 1,992 descriptions
| No. | Drug (Description in trials) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | Disease ID | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (-)-trans-delta-9-Tetrahydrocannabinol | [1] Dronabinol Dronabinol | [1] Dronabinol
Dronabinol
💬1. (-)-trans-delta-9-Tetrahydrocannabinol
| [2] CNR1 CNR1,CNR2 💬 | [4] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 [4] Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid sign ... | [1] 13 13 💬1. (-)-trans-delta-9-Tetrahydrocannabinol
| ||||||||||||
| 2 | (IM) AVONEX® | [1] Interferon beta-1a Interferon beta-1a | [1] Interferon beta-1a
Interferon beta-1a
💬2. (IM) AVONEX®
| [2] IFNAR1 IFNAR1,IFNAR2 💬 | [18] Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 [18] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infe ... | [1] 13 13 💬2. (IM) AVONEX®
| ||||||||||||
| 3 | (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide | - | - | - | - | [1] 13 13 💬3. (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide
| ||||||||||||
| 4 | 0,5 mg Fingolimod | [1] Fingolimod Fingolimod | [1] Fingolimod
Fingolimod
💬4. 0,5 mg Fingolimod
| [1] S1PR1 S1PR1 💬4. 0,5 mg Fingolimod
| [3] FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 [3] FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway ... | [1] 13 13 💬4. 0,5 mg Fingolimod
| ||||||||||||
| 5 | 0.25 mg RPC1063 | - | - | - | - | [3] 13 13, 96, 97 💬
| ||||||||||||
| 6 | 0.25mg RPC1063 | - | - | - | - | [2] 13 13, 97 💬
| ||||||||||||
| 7 | 0.5 mg RPC1063 | - | - | - | - | [2] 13 13, 97 💬
| ||||||||||||
| 8 | 0.5mg RPC1063 | - | - | - | - | [1] 13 13 💬8. 0.5mg RPC1063
| ||||||||||||
| 9 | 032166011 | - | - | - | - | [1] 13 13 💬9. 032166011
| ||||||||||||
| 10 | 033283045 | - | - | - | - | [1] 13 13 💬10. 033283045
|